General Principles of Medical Management

The Treatment of Epilepsy: Third Edition

Volumn , Issue , 2009, Pages 119-139

  Perucca, Emilio ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Adverse drug interaction avoidance; Combination therapy; Complete seizure control; Medical management principles; Subclinical epileptic activity suppression; Therapeutic response assessment and direct seizure observation; Treatment initiation and dose optimization

Indexed keywords

EID: 84872085258     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316667.ch9     Document Type: Chapter

References (84)

1. Perucca E, Beghi E, Dulac O, et al. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000; 41: 107-139.
2. Raspall-Chaure M, Neville BG, Scott RC. The medical management of the epilepsies in children: conceptual and practical considerations. Lancet Neurol 2008; 7: 57-69.
3. Birbeck GL, Hays RD, Cui X, Vickrey BG. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 2002; 43:535-538.
4. Perucca E, Kwan P. Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs 2005; 19: 897-908.
5. Harden CL, Maroof DA, Nikolov B, et al. The effect of seizure severity on quality of life in epilepsy. Epilepsy Behav 2007; 11: 208-211.
6. Smith D, Baker GB, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993; 34: 312-322.
7. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255-1260.
8. Gilliam FG, Fessler AJ, Baker G, et al. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004; 62: 23-27.
9. Holmes GL, Lenck-Santini PP. Role of interictal epileptiform abnormalities in cognitive impairment. Epilepsy Behav 2006; 8: 504-515.
10. Nashef L, Hindocha N, Makoff A. Risk factors in sudden death in epilepsy (SUDEP): the quest for mechanisms. Epilepsia 2007; 48:859-871.
11. Hermann B, Seidenberg M, Jones J. The neurobehavioural comorbidities of epilepsy: can a natural history be developed? Lancet Neurol 2008; 7:151-160.
12. Tellez-Zenteno JF, Patten SB, Jetté N, et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007; 48: 2336-2344.
13. Hesdorffer DC, Hauser WA, Olafsson E, et al. Depression and suicide attempt as risk factors for incident unprovoked seizures. Ann Neurol 2006; 59: 35-41.
14. Gilliam FG, Barry JJ, Hermann BP, et al. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol 2006; 5:399-405.
15. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61: 246-255.
16. Willmore LJ. Antiepileptic drugs and neuroprotection: current status and future roles. Epilepsy Behav 2005; 7(Suppl. 3): S25-S28.
17. Cendes F. Progressive hippocampal and extrahippocampal atrophy in drug resistant epilepsy. Curr Opin Neurol 2005; 18: 173-177.
18. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: Meta-analysis of controlled trials. Epilepsia 2001; 42:515-524.
19. Beghi E. The management of a first seizure. Still a major debate. Epilepsia 2008; 49(Suppl. 1): 1-61.
20. Shinnar S, Berg AT. Does antiepileptic drug therapy prevent the development of 'chronic' epilepsy? Epilepsia 1996; 37: 701-708.
21. Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 2005; 365: 2007-2013.
22. Wong M. Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. Epilepsia 2008; 49: 8-21.
23. Berg AT, Shinnar S, Levy SR, et al. How well can epilepsy syndromes be identified at diagnosis? A reassessment 2 years after initial diagnosis. Epilepsia 2000; 41: 1269-1275.
24. Leach JP, Lauder R, Nicolson A, Smith DF. Epilepsy in the UK: misdiagnosis, mistreatment, and undertreatment? The Wrexham area epilepsy project. Seizure 2005; 14: 514-520.
25. Miller LC, Drislane FW. Treatment strategies after a single seizure:rationale for immediate versus deferred treatment. CNS Drugs 2007; 21:89-99.
26. Berg AT, Shinnar S. The risk of seizure recurrence after a first unprovoked seizure: a quantitative review. Neurology 1991; 41: 965-972.
27. Musicco M, Beghi E, Solari A, et al. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. Neurology 1997; 49:991-998.
28. First Seizure Trial Group. Randomized clinical trial of the efficacy of antiepileptic drugs in reducing the risk of relapse after first unprovoked tonic-clonic seizure. Neurology 1993; 43: 478-483.
29. Hirtz D, Berg A, Bettis D, et al. Practice parameter: treatment of the child with a first unprovoked seizure. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2003; 60:166-175.
30. Kim LG, Johnson TL, Marson AG, et al. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol 2006; 5: 317-322.
31. Jacoby A, Gamble C, Doughty J, et al. Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures. Neurology 2007; 68: 1188-1196.
32. American Academy of Pediatrics. Committee on Quality Improvement, Subcommittee on Febrile Seizures. Practice parameter: Long-term treatment of the child with simple febrile seizures. Pediatrics 1999; 103:1307-1309.
33. Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, double-blind study of phenytoin for the prevention of posttraumatic seizures. N Engl J Med 1990; 323: 497-502.
34. Perucca E, Dulac O, Shorvon S, Tomson T. Harnessing the clinical potential of antiepileptic drug therapy: Dosage optimisation. CNS Drugs 2001; 15: 609-621.
35. Löscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 2006; 47: 1253-1284.
36. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007; 48: 1223-1244.
37. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402-408.
38. Richens A, Davidson DLW, Cartlidge NEF, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in adult-onset epilepsy. J Neurol Neurosurg Psychiatr 1994; 57: 682-687.
39. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-319.
40. Schmidt D, Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital and carbamazepine: individual variation in relation to seizure type. Neurology 1984; 34: 1252-1253.
41. Perucca E. Clinical pharmacokinetics of new generation antiepileptic drugs at the extremes of age. Clin Pharmacokin 2006; 45: 351-363.
42. Hadjiloizou SM, Bourgeois BF. Antiepileptic drug treatment in children. Exp Rev Neurother 2007; 7: 179-193.
43. Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006; 67(Suppl. 4): S28-S33.
44. Boggs JG. Elderly patients with systemic disease. Epilepsia 2001; 42(Suppl. 8): 18-23.
45. Perucca E, Berlowitz D, Birnbaum A, et al. Pharmacological and clinical aspects of antiepileptic drugs use in the elderly. Epilepsy Res 2006; 68(Suppl. 1): 49-63.
46. Saetre E, Perucca E, Isojarvi J, et al. An international multicenter randomized double-blind controlled trial of lamotrigine and sustainedrelease carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007; 48: 1292-1302.
47. Perucca E. Pharmacokinetics. In: Engel J Jr, Pedley TA, eds. Epilepsy - A Comprehensive Textbook. Philadelphia: Lippincott, Williams & Wilkins, 2008; 1151-1170.
48. Bialer M. Extended-release formulations for the treatment of epilepsy. CNS Drugs 2007; 21: 765-774.
49. Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889-926.
50. Rowan AJ, Binnie CD, Warfield CA, Meinardi H, Meijer JW. The delayed effect of sodium valproate on the photoconvulsive response in man. Epilepsia 1979; 20: 61-68.
51. Nau H, Hauck RS, Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 1991; 69: 310-321.
52. Perucca E, Albani F, Capovilla G, et al. Recommendations of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic Drugs. Epilepsia 2006; 46(Suppl. 5): 16-20.
53. Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 2007; 48: 1825-1832.
54. Laroche ML, Traore H, Merle L, et al. Quality of phenobarbital soliddosage forms in the urban community of Nouakchott (Mauritania). Epilepsia 2005; 46: 1293-1296.
55. Walker DM, Teach SJ. Update on the acute management of status epilepticus in children. Curr Opin Pediatr 2006; 18: 239-244.
56. Richens A, Dunlop A. Serum phenytoin levels in management of epilepsy. Lancet 1975; 2: 247-248.
57. Hermanns G, Noachtar S, Taxhorn I, et al. Systematic testing of medical intractability for carbamazepine, phenytoin and phenobarbital or primi done in monotherapy for patients considered for epilepsy surgery. Epilepsia 1996; 37: 675-679.
58. Perucca E. Pharmacoresistance in epilepsy. How should it be defined? CNS Drugs 1998; 10: 171-179.
59. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening of seizures. Epilepsia 1998; 39: 5-17.
60. Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs. Best practice guidelines for therapeutic drug monitoring: A position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276.
61. Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol Scand 2005; 112(Suppl. 181): 31-35.
62. Harden CL. Therapeutic safety monitoring: what to look for and when to look for it. Epilepsia 2000; 41(Suppl. 8): S37-S44.
63. Hakkarainen H. Carbamazepine vs diphenylhydantoin vs their combination in adult epilepsy. Neurology 1980; 30: 354.
64. Beghi E, Gatti G, Tonini C, et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomized, pragmatic, controlled trial. Epilepsy Res 2003; 57: 1-13.
65. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 13: 145-151.
66. Cramer JA, Fisher R, Ben-Menachem E, et al. New antiepileptic drugs:comparison of key clinical trials. Epilepsia 1999; 40: 590-600.
67. Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fund Clin Pharmacol 2001; 15: 405-417.
68. Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 2007; 48:1303-1307.
69. Patsalos PV, Perucca E. Clinically important drug interactions in epilepsy:general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 347-356.
70. Besag FMC, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39: 183-187.
71. Perucca E. What can we learn from clinical trials of new anticonvulsant drugs in epilepsy? Eur J Pain 2002; 6(Suppl. A): 35-44.
72. Deckers CLP, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000; 41: 1364-1374.
73. Brodie MJ, Yuen AWC, and 105 Study Group. Lamotrigine substitution study: Evidence for synergism with sodium valproate. Epilepsy Res 1997; 26: 423-432.
74. Rowan AJ, Meijer JWA, de Beer-Pawlikowski N, van der Geest P. Valproate ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983; 40: 797-802.
75. Pisani F, Oteri G, Russo R, et al. The efficacy of valproate-lamotrigine co-medication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40: 1141-1146.
76. Beardsley RS, Freeman JM, Appel FA. Anticonvulsant serum levels are useful only if the physician appropriately uses them: an assessment of the impact of providing serum level data to physicians. Epilepsia 1983; 24: 330-335.
77. Perucca E, Richens A. Antiepileptic drugs. Clinical aspects. In: Richens A, Marks V, eds. Therapeutic Drug Monitoring. Edinburgh: Churchill-Livingstone, 1983; 320-348.
78. Pisani F, Fazio A, Oteri G, et al. Sodium valproate and valpromide:potential interactions with carbamazepine in epileptic patients. Epilepsia 1986; 27: 548-552.
79. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000; 38: 191-204.
80. Specht U, Elsner H, May T, et al. Postictal serum levels of antiepileptic drugs for detection of noncompliance. Epilepsy Behav 2003; 4:487-495.
81. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008; 70: 2130-2136.
82. Jannuzzi G, Cian P, Fattore C, et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. Epilepsia 2000; 41:222-230.
83. Berg AT, Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology 1994; 44: 601-608.
84. Specchio LM, Beghi E. Should antiepileptic drugs be withdrawn in seizure-free patients? CNS Drugs 2004; 18: 201-212.